Cargando…
Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers
BACKGROUND: Beta-blocker therapies for cardiovascular comorbidities are often withheld in patients with chronic obstructive pulmonary disease (COPD) due to potential adverse effects on airway obstruction. We carried out a post hoc analysis to determine the efficacy and safety of aclidinium in patien...
Autores principales: | Chapman, Kenneth R., Wise, Robert A., Scirica, Benjamin M., Bhatt, Deepak L., Daoud, Sami Z., Lythgoe, Dan, Gil, Esther Garcia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532273/ https://www.ncbi.nlm.nih.gov/pubmed/34686204 http://dx.doi.org/10.1186/s12931-021-01861-2 |
Ejemplares similares
-
The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
por: Wise, Robert A, et al.
Publicado: (2021) -
Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial
por: Wise, Robert A., et al.
Publicado: (2021) -
High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment
por: Liao, Chun-Hou, et al.
Publicado: (2016) -
PRISMA-combined α-blockers and antimuscarinics for ureteral stent-related symptoms: A meta-analysis
por: Zhang, Yu-ming, et al.
Publicado: (2017) -
Use of Antimuscarinics in the Elderly
por: Patel, Bhavin, et al.
Publicado: (2009)